Pub Date : 2017-09-01DOI: 10.20959/WJPPS20179-9855
S. Satyasri
A simple, sensitive, accurate method was developed for the estimation of Irbesartan in tablets by RP-HPLC technique. Chromatographic conditions used are stationary phase standard ODS (150 mm x 4.6 mm, 5) column, mobile phase was orthophosphate buffer: methanol in the ratio of (50:50,v/v) and flow rate was maintained at 1 ml/min, detection wave length was 258 nm, column temperature was set to 30 o C and diluent was mobile phase conditions were finalized as optimized method. System suitability parameters were studied by injecting the standard six times and results were well under the acceptance criteria. Linearity study was carried out between 37.5 to 225 μg/ml levels, R 2 value was found to be as 0.999. Precision was found to be 1.3 for repeatability and 0.8 for intermediate precision. LOD and LOQ are 0.205 μg/ml and 0.623 μg/ml, respectively. By using above method assay of marketed formulation was carried out 99.89% was present.
建立了简便、灵敏、准确的反相高效液相色谱法测定厄贝沙坦片剂中厄贝沙坦含量的方法。色谱条件为固定相标准ODS (150 mm × 4.6 mm, 5)柱，流动相为正磷酸盐缓冲液:甲醇，比例为(50:50,v/v)，流速为1 ml/min，检测波长为258 nm，柱温为30℃，流动相为稀释液，确定最佳色谱条件。通过注入6次标准液，对系统适宜性参数进行了研究，结果完全符合验收标准。在37.5 ~ 225 μg/ml浓度范围内进行线性研究，r2值为0.999。重复性精密度为1.3，中间精密度为0.8。定量限和定量限分别为0.205 μg/ml和0.623 μg/ml。采用该方法对市售制剂进行了检测，回收率达99.89%。
{"title":"A NOVEL METHOD DEVELOPMENT FOR THE ESTIMATION OF IRBESARTAN IN TABLETS BY USING REVERSE PHASE LIQUID CHROMATOGRAPHY","authors":"S. Satyasri","doi":"10.20959/WJPPS20179-9855","DOIUrl":"https://doi.org/10.20959/WJPPS20179-9855","url":null,"abstract":"A simple, sensitive, accurate method was developed for the estimation of Irbesartan in tablets by RP-HPLC technique. Chromatographic conditions used are stationary phase standard ODS (150 mm x 4.6 mm, 5) column, mobile phase was orthophosphate buffer: methanol in the ratio of (50:50,v/v) and flow rate was maintained at 1 ml/min, detection wave length was 258 nm, column temperature was set to 30 o C and diluent was mobile phase conditions were finalized as optimized method. System suitability parameters were studied by injecting the standard six times and results were well under the acceptance criteria. Linearity study was carried out between 37.5 to 225 μg/ml levels, R 2 value was found to be as 0.999. Precision was found to be 1.3 for repeatability and 0.8 for intermediate precision. LOD and LOQ are 0.205 μg/ml and 0.623 μg/ml, respectively. By using above method assay of marketed formulation was carried out 99.89% was present.","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"6 1","pages":"908-913"},"PeriodicalIF":0.0,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73161638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-09-01DOI: 10.20959/WJPPS20179-10164
A. Naik
Shock is a state of circulatory impairment characterized by defective tissue perfusion resulting in abnormal cellular function and metabolism & inadequate tissue perfusion to meet tissue demands. [1] Parturition is a natural process. In majority of the cases it happens without any complications. In obstetrics the standard rule is non interference unless called for. Interfering with a normal labor unnecessarily is a starting point for many problems. However a normal labor can turn into abnormality at any point of time suddenly with no warning. Prompt recognition and management can improve maternal and fetal outcome in obstetric shock.
{"title":"OBSTETRIC SHOCK AND ITS MANAGEMENT","authors":"A. Naik","doi":"10.20959/WJPPS20179-10164","DOIUrl":"https://doi.org/10.20959/WJPPS20179-10164","url":null,"abstract":"Shock is a state of circulatory impairment characterized by defective tissue perfusion resulting in abnormal cellular function and metabolism & inadequate tissue perfusion to meet tissue demands. [1] Parturition is a natural process. In majority of the cases it happens without any complications. In obstetrics the standard rule is non interference unless called for. Interfering with a normal labor unnecessarily is a starting point for many problems. However a normal labor can turn into abnormality at any point of time suddenly with no warning. Prompt recognition and management can improve maternal and fetal outcome in obstetric shock.","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"26 1","pages":"2045-2052"},"PeriodicalIF":0.0,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73273613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-09-01DOI: 10.20959/WJPPS20179-10087
N. Sharma
{"title":"COMPARATIVE EVALUATION OF STANNOUS FLUORIDE VS POTASSIUM NITRATE IN THE MANAGEMENT OF DENTINAL HYPERSENSITIVITY","authors":"N. Sharma","doi":"10.20959/WJPPS20179-10087","DOIUrl":"https://doi.org/10.20959/WJPPS20179-10087","url":null,"abstract":"","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"10 1","pages":"1863-1870"},"PeriodicalIF":0.0,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81672504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-09-01DOI: 10.20959/WJPPS20179-10046
S. Bandgar
{"title":"SOLUBILITY ENHANCEMENT OF POORLY SOLUBLE DRUG BY VARIOUS TECHNIQUES","authors":"S. Bandgar","doi":"10.20959/WJPPS20179-10046","DOIUrl":"https://doi.org/10.20959/WJPPS20179-10046","url":null,"abstract":"","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"263 1","pages":"1405-1416"},"PeriodicalIF":0.0,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76294056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-09-01DOI: 10.20959/WJPPS20179-10039
A. Kannan
{"title":"AN INTERESTING CASE SERIES OF FLORID GRANULOMATOUS REACTION IN HODGKIN’S LYMPHOMA","authors":"A. Kannan","doi":"10.20959/WJPPS20179-10039","DOIUrl":"https://doi.org/10.20959/WJPPS20179-10039","url":null,"abstract":"","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"10 1","pages":"1367-1372"},"PeriodicalIF":0.0,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87618599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-09-01DOI: 10.20959/wjpps20179-9852
Shyam R. Annapure
{"title":"SYNTHESIS AND CHARACTRISATION OF NEW MN (II), FE (III), CO (II), METAL COMPLEXES DERIVED FROM 2-HYDROXY 3-METHOXY BENZALDEHYDE AND DHA","authors":"Shyam R. Annapure","doi":"10.20959/wjpps20179-9852","DOIUrl":"https://doi.org/10.20959/wjpps20179-9852","url":null,"abstract":"","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"40 1","pages":"899-907"},"PeriodicalIF":0.0,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86439425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-09-01DOI: 10.20959/WJPPS20179-10156
R. Jayesh
{"title":"A CONCEPT OF JIVANTYADI GHRITA TARPANA ALONG WITH SHODHANA NASYA IN THE MANAGEMNNT OF SHUSHKAKSHIPAKA (DRY EYE)","authors":"R. Jayesh","doi":"10.20959/WJPPS20179-10156","DOIUrl":"https://doi.org/10.20959/WJPPS20179-10156","url":null,"abstract":"","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"1 1","pages":"2041-2044"},"PeriodicalIF":0.0,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86509380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-09-01DOI: 10.20959/WJPPS20179-10097
G. T. Rani
In this study a sensitive, simple and accurate spectrophotometric method is suggested for the determination of Ticagrelor in bulk and pharmaceutical dosage form based on the formation of an ion-pair complex between the drug and bromothymol blue in a buffer solution at pH 1.2 (0.1N HCl). The optimum conditions for the analysis of drug is established and Ticagrelor was found to exhibit maximum absorbance at 414nm with chloroform as solvent. The present method is validated as per guidelines of the International Conference on Harmonization (ICH) including parameters like linearity, accuracy, and precision, limit of detection and limit of quantification. The Beer’s law is found to be in concentration range of 50-400μg/ml and the regression line equation is Y= 0.0032x 0.0012 with correlation coefficient of 0.999. The percentage recovery is found to be 100.1-100.8%. The precision is evaluated and relative standard deviation (RSD) is found to be less than 2%. The values of LOD & LOQ are 0.32 & 1.09 respectively. The results suggest that this method can be employed for routine analysis of Ticagrelor in bulk and pharmaceutical formulations.
{"title":"DEVELOPMENT AND VALIDATION OF NEW SPECTROPHOTOMETRIC METHOD FOR THE DETERMINATION OF TICAGRELOR IN BULK AND PHARMACEUTICAL FORMULATION","authors":"G. T. Rani","doi":"10.20959/WJPPS20179-10097","DOIUrl":"https://doi.org/10.20959/WJPPS20179-10097","url":null,"abstract":"In this study a sensitive, simple and accurate spectrophotometric method is suggested for the determination of Ticagrelor in bulk and pharmaceutical dosage form based on the formation of an ion-pair complex between the drug and bromothymol blue in a buffer solution at pH 1.2 (0.1N HCl). The optimum conditions for the analysis of drug is established and Ticagrelor was found to exhibit maximum absorbance at 414nm with chloroform as solvent. The present method is validated as per guidelines of the International Conference on Harmonization (ICH) including parameters like linearity, accuracy, and precision, limit of detection and limit of quantification. The Beer’s law is found to be in concentration range of 50-400μg/ml and the regression line equation is Y= 0.0032x 0.0012 with correlation coefficient of 0.999. The percentage recovery is found to be 100.1-100.8%. The precision is evaluated and relative standard deviation (RSD) is found to be less than 2%. The values of LOD & LOQ are 0.32 & 1.09 respectively. The results suggest that this method can be employed for routine analysis of Ticagrelor in bulk and pharmaceutical formulations.","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"15 1","pages":"1587-1595"},"PeriodicalIF":0.0,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86319168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-09-01DOI: 10.20959/WJPPS20179-10154
Venkatrajan Rangaraju
Objective: Identifying, Analyzing and developing prevention strategies for medication errors in cancer patients receiving chemotherapy. Methods: A prospective, open labeled, Observational study was conducted in the Department of Medical Oncology, in a tertiary care hospital in Tamil Nadu, India. Patients who came to receive chemotherapy during the period of 6 months from Jan 2016 to June 2016 were included in the study. Medication history interview, reconstitution procedures, administration procedures and chemotherapy chart review were done. Drugs administered for other co morbid conditions were not been considered for assessing medication errors. Medication errors were assessed based on the NCCMERP index and statistical analysis was done by using SPSS tool. Prevention strategies were developed to rectify the medication errors and factors which influence the medication error. Result: Medication Error among the patients receiving chemotherapy was identified to be 51.08%, of which, prescribing error was 19.79%, administration error was 27.08%, wrong dose was 41.66%, wrong drug error was 3.12% and wrong strength was 8.33%. Based on the NCCMERP index, the majority of errors (70%) fell in the category Error, No Harm, followed by which 34% belongs to no error and 2% with Error, Harm and there was no death occurred due to medication error. Further, the errors were grouped into 8 categories (Category A to Category I). The majority of errors (35%) fall into category A. Among various chemotherapeutic agent, 5-Fluorouracil was found to have more medication WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES SJIF Impact Factor 6.647 Volume 6, Issue 9, 1759-1769 Research Article ISSN 2278 – 4357 Article Received on 17 July 2017, Revised on 06 August 2017, Accepted on 28 August 2017 DOI: 10.20959/wjpps20179-10154 *Corresponding Author
{"title":"ASSESSMENT OF MEDICATION ERRORS IN CHEMOTHERAPY RECEIVING PATIENTS IN TERTIARY CARE HOSPITAL","authors":"Venkatrajan Rangaraju","doi":"10.20959/WJPPS20179-10154","DOIUrl":"https://doi.org/10.20959/WJPPS20179-10154","url":null,"abstract":"Objective: Identifying, Analyzing and developing prevention strategies for medication errors in cancer patients receiving chemotherapy. Methods: A prospective, open labeled, Observational study was conducted in the Department of Medical Oncology, in a tertiary care hospital in Tamil Nadu, India. Patients who came to receive chemotherapy during the period of 6 months from Jan 2016 to June 2016 were included in the study. Medication history interview, reconstitution procedures, administration procedures and chemotherapy chart review were done. Drugs administered for other co morbid conditions were not been considered for assessing medication errors. Medication errors were assessed based on the NCCMERP index and statistical analysis was done by using SPSS tool. Prevention strategies were developed to rectify the medication errors and factors which influence the medication error. Result: Medication Error among the patients receiving chemotherapy was identified to be 51.08%, of which, prescribing error was 19.79%, administration error was 27.08%, wrong dose was 41.66%, wrong drug error was 3.12% and wrong strength was 8.33%. Based on the NCCMERP index, the majority of errors (70%) fell in the category Error, No Harm, followed by which 34% belongs to no error and 2% with Error, Harm and there was no death occurred due to medication error. Further, the errors were grouped into 8 categories (Category A to Category I). The majority of errors (35%) fall into category A. Among various chemotherapeutic agent, 5-Fluorouracil was found to have more medication WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES SJIF Impact Factor 6.647 Volume 6, Issue 9, 1759-1769 Research Article ISSN 2278 – 4357 Article Received on 17 July 2017, Revised on 06 August 2017, Accepted on 28 August 2017 DOI: 10.20959/wjpps20179-10154 *Corresponding Author","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"3 1","pages":"1759-1769"},"PeriodicalIF":0.0,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91532973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-09-01DOI: 10.20959/WJPPS20179-10116
Chowdary K. P. R.
The objective of the present study is optimization of Valsartan tablet formulation employing βCD, Starch 1500, and Soluplus by 2 3 factorial design to achieve NLT 85% dissolution in 10 min. Eight Valsartan tablet formulations were prepared using selected combinations of the three factors as per 2 3 factorial design. Valsartan tablets were prepared by direct compression method and were evaluated. The individual and combined effects of the three factors βCD, Starch 1500 and Soluplus are highly significant (P < 0.01) in influencing the dissolution rate of Valsartan tablets. Valsartan tablet formulations Fb,Fab, Fbc and Fabc disintegrated rapidly and gave very rapid dissolution of Valsartan, 92.4%, 99.4%, 96.2% and 99.2% in 10 min respectively. The increasing order of dissolution rate (K1) observed with various formulations was F1< Fc< Fa< Fac< Fb< Fbc< Fab
{"title":"FORMULATION DEVELOPMENT AND OPTIMIZATION OF VALSARTAN TABLETS EMPLOYING βCD STARCH 1500 AND SOLUPLUS","authors":"Chowdary K. P. R.","doi":"10.20959/WJPPS20179-10116","DOIUrl":"https://doi.org/10.20959/WJPPS20179-10116","url":null,"abstract":"The objective of the present study is optimization of Valsartan tablet formulation employing βCD, Starch 1500, and Soluplus by 2 3 factorial design to achieve NLT 85% dissolution in 10 min. Eight Valsartan tablet formulations were prepared using selected combinations of the three factors as per 2 3 factorial design. Valsartan tablets were prepared by direct compression method and were evaluated. The individual and combined effects of the three factors βCD, Starch 1500 and Soluplus are highly significant (P < 0.01) in influencing the dissolution rate of Valsartan tablets. Valsartan tablet formulations Fb,Fab, Fbc and Fabc disintegrated rapidly and gave very rapid dissolution of Valsartan, 92.4%, 99.4%, 96.2% and 99.2% in 10 min respectively. The increasing order of dissolution rate (K1) observed with various formulations was F1< Fc< Fa< Fac< Fb< Fbc< Fab <Fabc. The polynomial equation describing the relationship between the response, percent drug dissolved in 10min (Y) and the levels of βCD (X1), Starch 1500 (X2) and Soluplus (X3) based on the observed results was found to be Y = 68.625 + 4.375(X1) + 27.375(X2) 2.375(X1 X2)+ 3.375(X3) + 0.125(X1 X3) 1.875(X2 X3) 0.625(X1 X2 X3) Based on the above equation, the formulation of optimized Valsartan tablets with NLT 85% dissolution in 10 min require βCD at 1:3.5 ratio of drug: βCD, Starch 1500 at 24.37% of drug and βCD content, and Soluplus at 1% of drug and βCD content. The optimized Valsartan tablet formulation gave 85.75% dissolution in 10min fulfilling the target dissolution requirement. Hence formulation of Valsartan tablets with NLT 85% dissolution in 10 min could be optimized by 2 3 factorial design. WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES SJIF Impact Factor 6.647 Volume 6, Issue 9, 1674-1683 Research Article ISSN 2278 – 4357 *Corresponding Author Prof. Chowdary K. P. R. Chairman, BOS in","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"51 1","pages":"1674-1683"},"PeriodicalIF":0.0,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89167552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：